AU2002242725A1 - Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro - Google Patents

Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro

Info

Publication number
AU2002242725A1
AU2002242725A1 AU2002242725A AU2002242725A AU2002242725A1 AU 2002242725 A1 AU2002242725 A1 AU 2002242725A1 AU 2002242725 A AU2002242725 A AU 2002242725A AU 2002242725 A AU2002242725 A AU 2002242725A AU 2002242725 A1 AU2002242725 A1 AU 2002242725A1
Authority
AU
Australia
Prior art keywords
ctl
vaccination
mhc
hiv
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002242725A
Inventor
Florence Buseyne
Jean-Michel Heard
Delphine Marsac
Marie-Louise Michel
Yves Riviere
Olivier Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2002242725A1 publication Critical patent/AU2002242725A1/en
Abandoned legal-status Critical Current

Links

AU2002242725A 2001-02-27 2002-02-26 Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro Abandoned AU2002242725A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60/271,432 2001-02-27

Publications (1)

Publication Number Publication Date
AU2002242725A1 true AU2002242725A1 (en) 2002-09-24

Family

ID=

Similar Documents

Publication Publication Date Title
IL150602A0 (en) Proteosome influenza vaccine
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
HUP0402067A2 (en) Vaccines
CY1105779T1 (en) HUMAN PAMMA VIRUS VACCINE WITH DISASSEMBLED AND REASSEMBLED VIRUS-LIKE PARTICLES
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
EP1878424A3 (en) Novel vaccine
HUP0004327A1 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
WO2002080965A3 (en) Vaccine composition
WO2008057529A3 (en) Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
AP1872A (en) Virus-like particles of human papillomavirus.
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
TWI349557B (en) Use of hpv 16 and hpv 18 vlps for vaccine preparation
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
HUP0204216A2 (en) A new use of antibodies as vaccines
FR2717081B1 (en) Retropeptides, antibodies to the latter, and their uses for vaccination and in vitro diagnosis.
AU2002242725A1 (en) Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
DE69637435D1 (en) SAPONIN COMPOSITIONS AND ITS USE
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2002070004A3 (en) Papillomavirus vaccines
AU2002223860A1 (en) Nucleic acid vaccine comprising a fusion protein including an adjuvant sequence from a plant viral coat protein
WO2001026680A3 (en) Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
WO2004098636A8 (en) Vaccinating against infectious diseases using proteosomes
RU2001127052A (en) The strain of the Ebola virus "Zaire Ch-15" for conducting model experiments and the preparation of diagnostic and vaccine preparations